Jin-Yuan Shih

Oncology — National Taiwan University Hospital, Taiwan

LeadR Profile

1 294 ScienceLeadR Reputation 1294
Network Map

Oncology

Subspecialties: Pulmonology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1991 - 2026

Source: PubMed

National Taiwan University Hospital

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 368

Citations

Citations: 21 007 1st author: 21 Last author: 92 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Response to comments on "Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy".
cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, exons, lung neoplasms, small cell lung carcinoma, therapeutics, mutation, chemotherapy
J Formos Med Assoc20260
Few-Shot Lung Cancer Classification via Electronic Nose Using Large Language Models: A Multicentre Prospective Study.
language, lung, respiratory tract diseases, neoplasms, classification, electronic nose, lung neoplasms, diagnosis, nose, prospective studies
Respirology20260
Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.
neoplasms, carcinoma, non-small-cell lung, drug therapy, afatinib, chemotherapy
Target Oncol20260
Stanniocalcin 2-Induced Autophagy Confers Resistance of Lung Cancer Cells to EGFR Inhibition via the ERK/Beclin 1 Signaling.
cells, lung, autophagy, rna, small interfering, neoplasms, lung neoplasms, beclin-1, vacuoles
Cancer Med20260
Mechanisms of Acquired Resistance Following Dual EGFR/MET Inhibition in MET-Amplified EGFR TKI-Resistant Lung Cancer.
cells, lung, neoplasms, lung neoplasms, cell line, therapeutics
Mol Cancer Ther20260

Clinical Studies 11

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Chair: 1

By phase:

Phase 3 5
N/A 4
Phase 2 1
Phase 2/Phase 3 1

By status:

Active not recruiting 6
Completed 3
Recruiting 1
Unknown 1

By type:

Interventional 7
Observational 4

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 8

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Pan Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
NCT06418412 — cells, epidemiology, lung, neoplasms, carcinoma, non-small-cell lung, exons, lung neoplasms, small cell lung carcinoma, carcinoma
N/ARecruiting2024
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566 — cells, lung, neoplasms, drug therapy, lung neoplasms, small cell lung carcinoma, topotecan, chemotherapy, carcinoma
Phase 3Active not recruiting2023

LeadR Networks

Main global connection map